Eli Lilly CSO Meeting Highlights: Obesity Pipeline Shows Multiple Breakthroughs, Retatrutide Potential Reaffirmed

Overview

This report is a meeting summary following Morgan Stanley's discussion with Eli Lilly's Chief Scientific Officer (CSO), focusing on the company's R&D pipeline: product iteration and positioning in the obesity/incretin space, progress in Alzheimer's and cardiovascular diseases, AI-enabled drug discovery, and recent business development (M&A) updates. Morgan Stanley maintains its 'Overweight' rating and $1,344 target price for Eli Lilly, optimistic about its diversified pipeline centered on obesity and long-term growth potential.

Core views

The obesity field remains Eli Lilly's strategic core. Management emphasizes building the broadest product portfolio to meet diverse patient needs and acknowledges that early market positioning/segmentation judgments may only be validated once products are actually launched. Long-term, the company believes oral drug Foundayo will become the market leader due to convenience and cost advantages. Retatrutide (Reta, GLP-1/GIP/glucagon triple agonist) was the focus of this meeting. Management is very excited about the recently announced Phase III obesity data, believing it validates their core hypothesis for high-BMI patients (BMI 40+). More notably, low-dose Reta has already shown superior weight loss efficacy, tolerability, and dose-escalation time compared to Tirzepatide, positioning it as a potential 'workhorse' for lower BMI patients. Regarding safety, management is highly confident given extensive long-term patient usage data. Cardiovascular risk data from the TRIUMPH-3 trial is expected in the coming months, which will be key to fully dispelling concerns about Reta's cardiovascular risk. Eloralintide (selective amylin analog) in development is positioned as an alternative for patients intolerant to incretins. Phase II monotherapy has completed, and Phase II combination with Tirzepatide is ongoing. For longer-acting monthly incretin formulations, while management is uncertain about necessity, they indicate they won't rule out any technological approach, believing monthly formulations may have a role in the maintenance treatment phase. Regarding non-obesity indication expansion, management expresses high expectations for immunology (Tirzepatide + Taltz combination therapy, efficacy appears weight-independent) and Reta for osteoarthritis (one of the strongest efficacy signals in the pain field).

Analysis framework

Through direct dialogue with the company's top R&D leadership, Morgan Stanley employs a 'pipeline stratification validation' framework: first confirming the positioning and iteration logic of core commercial products (Tirzepatide, Foundayo), then deeply evaluating clinical data quality and market potential of next-generation blockbuster products (Reta, Eloralintide), and finally examining platform technology (AI drug discovery) and external expansion (M&A) as supplements to long-term competitiveness. This inside-out, near-to-far validation approach helps assess Eli Lilly's sustained leading position in the obesity super-track.

Methodology notes

• Valuation MethodPE/PEG valuation

  P/E Multiple Valuation

  The report uses 27x P/E to value Eli Lilly, which is close to the company's 10-year average (28x) and significantly higher than industry average (~15x), reflecting the institution's view that Eli Lilly's high growth and pipeline option value deserve a premium

• Industry Analysis FrameworkProduct life cycle

  Product Iteration and Lifecycle Management

  In the innovative drug industry, leading companies typically need to layout next-generation products before core products peak, forming a梯队 of 'marketed products-R&D pipeline-early-stage pipeline'. Eli Lilly's tiered layout with Tirzepatide (current workhorse) → Reta (next-gen injection) → Foundayo (oral) exemplifies this framework

• Event Gaming and Behavioral FinanceExpectation Gap/Expectation Management

  Expectation Management Before Clinical Data Readouts

  Reta's TRIUMPH-3 cardiovascular data is due in the coming months, and management emphasized good safety data during the meeting - typical expectation management behavior: guiding the market to form positive expectations before key catalysts to reduce negative surprise risk

Key data

• Target Price$1,344Based on 27x P/E multiple, corresponding to FY2027-2028 EPS of $49.76
• Current Stock Price$1,082.92Closing price on May 27, 2026
• Market Cap~$970.2 billion$970.2 billion USD
• 52-Week Stock Range$624.00–$1,133.04
• 2026-2028 EPS Forecast$39.91 / $47.09 / $57.77Morgan Stanley forecast, 2025 actual $24.20
• Recent M&A Total ConsiderationUp to ~$3.8 billionCurevo up to $1.5B + LimmaTech up to $780M + Vaccine Company up to $1.55B

Impact & implications

The report believes Eli Lilly's leadership in obesity will be consolidated through product iteration: Tirzepatide continues to gain market share, Reta is expected to expand to broader patient groups with superior efficacy-tolerability profile, and Foundayo opens up the oral market ceiling. Expansion into non-obesity indications (immunology, osteoarthritis, Alzheimer's) will further unlock growth potential. Although the recent vaccine and infectious disease acquisitions are not large in amount, they align with the company's BD strategy of 'platform validation + long-term vision + under-competitive fields', helping reduce dependence on the single obesity track. AI drug R&D capabilities (Tune Labs, NVIDIA partnership, supercomputing) form the infrastructure for long-term competitiveness.

Risks

• Foundayo/Orforglipron approval delay or post-launch commercialization underperformance
• Eloralintide and Retatrutide development terminated before approval
• Competitor pipeline data in diabetes/obesity poses threat
• Alzheimer's drug delivery route may become clinical challenge
• Kelonia/KLN-1010 durability issues remain to be verified

What to watch

• TRIUMPH-3 trial cardiovascular risk data (within next few months)
• Retatrutide obesity indication FDA submission progress (expected Q2 2026)
• Kisunla Alzheimer's Phase III preventive trial data (2027)
• Kelonia/KLN-1010 Phase I data update at ASCO
• BIIB tau ASO Phase II complete data at AAIC